Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28047920 | 0.98 | KDM4E (0.53) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL6844857 | 0.84 | KDM4E (0.55) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL31125276 | 0.84 | KDM4E (0.55) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL23243427 | 0.84 | KDM4E (0.55) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL3746157 | 0.84 | PTGDR2 (0.53) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL31053264 | 0.82 | KDM4E (0.53) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL24102358 | 0.82 | DGAT1 (0.52) | KDM4EGLAPTGDR2MYCNR4A1 | |
| SCHEMBL1400054 | 0.82 | KDM4E (0.53) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL31529596 | 0.82 | KDM4E (0.58) | KDM4EGLAPTGDR2APEX1MYC | |
| SCHEMBL25612072 | 0.82 | KDM4E (0.58) | KDM4EGLAPTGDR2APEX1MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949668-B2 | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound | TEIJIN LIMITED (JP) | 2005-09-27 | — | — | US | claimed |
| US-20050014966-A1 | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound | TEIJIN LIMITED (JP) | 2005-01-20 | — | — | US | claimed |
| EP-1460059-A1 | PROCESS FOR PRODUCING 5-(3-CYANOPHENYL)-3-FORMYLBENZOIC ACID COMPOUND | TEIJIN LIMITED (JP) | 2004-09-22 | — | — | EP | claimed |
| CN-110862327-A | Preparation method of 5-bromo-2-hydroxyanthranilic acid | 宿迁远扬生物科技有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1565443-A4 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1751091-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | Elan Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6949668-B2 | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound | TEIJIN LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1565443-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050014966-A1 | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound | TEIJIN LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1460059-A1 | PROCESS FOR PRODUCING 5-(3-CYANOPHENYL)-3-FORMYLBENZOIC ACID COMPOUND | TEIJIN LIMITED (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | KDM4E 3339/4885GLA 7/4885PTGDR2 1687/4885 |
| US-20050014966-A1 | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound | PAH, CA5B, PCCA | KDM4E 430/4885GLA 2466/4885PTGDR2 2605/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | KDM4E 3826/4885GLA 7/4885PTGDR2 2345/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | KDM4E 4405/4885GLA 126/4885PTGDR2 4578/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | KDM4E 3339/4885GLA 7/4885PTGDR2 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.